What is NVS's current stock price?

As of now, NVS is trading at $163.10, with a daily change of +1.16%.

What are the risks associated with NVS stock?

NVS has Low, risk level based on volatility, sector strength, volume, investor confidence and outlook.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

NVS Stock Analysis & IQ Rating | Novartis AG

NVS

Novartis AG

$163.10

+$1.87 | +1.16%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$163.42

MKT CAP

$342.99B

52W Low

$97.72

VOL

$1.84M

P/E Ratio

22.8

AVG VOL

$2.14M

RSI

80.80

TREND

Uptrend

NVS Stock IQ

Login to see Novartis AG (NVS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

NVS Target Price

Login to display

Strengths

NVS Rewards

Earnings are forecast to grow

NVS Rewards

Upgraded on attractively valued

NVS Rewards

Trading below its fair value

Technical Indicators

NVS Technical Indicators

5+ Days Up

NVS Price Performance

$143.58 (+13.60%)

$127.4 (+28.02%)

$122.82 (+32.80%)

$111.42 (+46.38%)

1year

6month

3month

1month

NVS Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

NVS Analysts Opinion

NVS Analysts opinion is negative and it remained unchanged from the past 3 months

NVS Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

70%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

60%

NVS Street Sentiment

NVS Street Sentiment is bullish and have positive views on the near-term outlook

NVS Risk Level

NVS has Low risk level

Low

LOW

HIGH

NVS Performance Sentiment

Sentiments overview associated with events and the stock performance

70%

26%

Positive

Negative

19 out of 27
events present

7 out of 27
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$163.10

Resistance
Price

$141.00

Current Price Range

$163.10

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

67%

Buy

Hold

Sell

Consensus Rating

BUY

2

1

0

Date

Action

Rating

Firm

Dec 16, 2025

Reiterate

Neutral

Guggenheim

Dec 10, 2025

Upgrade

Overweight

JP Morgan

Dec 09, 2025

Upgrade

Overweight

JP Morgan

Nov 20, 2025

Upgrade

Buy

Morgan Stanley

NVS Latest Analysis +

NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia . Novartis posts positive phase III ALIGN data for Vanrafia in IgAN showing slower kidney decline as it eyes full approval in 2026.

Fri Feb 13, 2026

$163.10 | +1.16%

Activity

Novartis Reports Positive Data From Phase III ALIGN Study For Vanrafia In IgA Nephropathy . (RTTNews) - Novartis (NVS) announced that final results from a phase 3 trial of Vanrafia support slowing of kidney function decline in patients with IgA nephropathy.

Fri Feb 13, 2026

$163.10 | +1.16%

Activity

ARWR: Strong Start for REDEMPLO Commercialization. By Business UpdateFirst Commercial Sales of REDEMPLO®Following its approval in November 2025 Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) recently announced encouraging news from the early commercial launch of REDEMPLO (plozasiran) as a treatment for adults suffering from familial chylomicronemia syndrome (FCS). Even with the Thanksgiving Christmas and New Years holidays the company reported that over 100 prescriptions for REDEMPLO have been rec

Wed Feb 11, 2026

$160.06 | +1.18%

Activity

Novartis: Value Price Growth Pipeline.

Thu Feb 5, 2026

$153.95 | +0.68%

Potential

Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead. Swiss pharmaceutical NVS) reported fourth-quarter 2025 results on Wednesday.The company'.s net sales 1% year over year to $13.34 billion missing Wall Street'.s . On a constant-currency (cc) basis sales were down 1%.Generic competition had a negative impact of 15 percentage points including a negative impact of 3 percentage points from revenue deduction adjustments in the United States mainly related to Entresto and Promact

Wed Feb 4, 2026

$152.91 | +2.04%

Potential

Novartis Beats on Q4 Earnings Entresto Generics Pressure Sales. NVS tops Q4 EPS estimates as margins expand but revenues miss the mark amid United States generics hitting Entresto and Promacta reshaping its growth mix.

Wed Feb 4, 2026

$152.91 | +2.04%

Earnings

Novartis reports mixed Q4 results. initiates FY26 soft outlook.

Wed Feb 4, 2026

$152.91 | +2.04%

Earnings

Novartis reports mixed Q4 results. initates FY26 soft outlook.

Wed Feb 4, 2026

$152.91 | +2.04%

Earnings

Novartis Q4 Profit Down Sales Rise. Sees Higher Sales In FY26 . (RTTNews) - Swiss drug major Novartis AG (NVS) reported Wednesday lower profit in its fourth quarter despite sales growth. Further the company lifted dividend and issued fiscal 2026 outlook expecting lower core operating income and higher net sales.

Wed Feb 4, 2026

$152.91 | +2.04%

Activity

Earnings

Novartis delivered high single-digit sales growth achieved 40% core margin and further advanced the pipeline in 2025.

Wed Feb 4, 2026

$152.91 | +2.04%

Activity

Runners Also Watch

Close Price

Change

PFE

Pfizer

27.58

+0.42%

SNY

Sanofi

46.01

-2.17%

TEVA

Teva Pharma

33.98

+0.18%

REGN

Regeneron Pharma

803.17

+2.49%

ARWR

Arrowhead Pharmaceuticals

63.82

+2.31%

FAQ About NVS Stock Insights

What is NVS current stock price?

What are NVS stock strengths?

What is NVS Risk Level?

What is NVS market cap and volume?

What is NVS current Stock IQ?

Should I buy NVS stock right now?

Is NVS a Strong Buy right now?

What does a 'Strong Buy' rating mean for NVS?

What does a 'Strong Sell' rating mean for NVS?

What factors influence NVS's Stock IQ?

Explore our NVS Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored NVS Stock Strategies
Effective Risk Management

FIND US ON

Receive our NVS Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

NVS

Novartis AG

Set Alerts

Current Price

$163.10

+$1.87 | +1.16%

52W High

$163.42

MKT CAP

$342.99B

52W Low

$97.72

VOL

$1.84M

P/E Ratio

22.8

AVG VOL

$2.14M

RSI

80.80

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Runners Also Watch

Symbol

Close

Change

PFE

Pfizer

27.58

+0.42%

SNY

Sanofi

46.01

-2.17%

TEVA

Teva Pharma

33.98

+0.18%

REGN

Regeneron Pharma

803.17

+2.49%

ARWR

Arrowhead Pharmaceuticals

63.82

+2.31%

NVS Price Performance

$143.58 (+13.60%)

$127.4 (+28.02%)

$122.82 (+32.80%)

$111.42 (+46.38%)

1year

6month

3month

1month

NVS Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

NVS Analysts Opinion

NVS Analysts opinion is negative and it remained unchanged from the past 3 months

NVS Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

70%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

60%

NVS Street Sentiment

NVS Street Sentiment is bullish and have positive views on the near-term outlook

NVS Risk Level

NVS has Low risk level

Low

LOW

HIGH

NVS Performance Sentiment

Sentiments overview associated with events and the stock performance.

70%

26%

Positive

Negative

19 out of 27
events present

7 out of 27
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$163.10

Resistance
Price

$141.00

Current Price Range

$163.10

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

67%

Buy

Hold

Sell

Consensus Rating

BUY

2

1

0

Date

Action

Rating

Firm

Dec 16, 2025

Reiterate

Neutral

Guggenheim

Dec 10, 2025

Upgrade

Overweight

JP Morgan

Dec 09, 2025

Upgrade

Overweight

JP Morgan

Nov 20, 2025

Upgrade

Buy

Morgan Stanley

NVS Stock IQ

Login to unlock Novartis AG (NVS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

NVS Rewards

Earnings are forecast to grow

NVS Rewards

Upgraded on attractively valued

NVS Rewards

Trading below its fair value

Technical Indicators

NVS Technical Indicators

5+ Days Up

NVS Latest Analysis

NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia . Novartis posts positive phase III ALIGN data for Vanrafia in IgAN showing slower kidney decline as it eyes full approval in 2026.

Fri Feb 13, 2026

$163.10 | +1.16%

Activity

Novartis Reports Positive Data From Phase III ALIGN Study For Vanrafia In IgA Nephropathy . (RTTNews) - Novartis (NVS) announced that final results from a phase 3 trial of Vanrafia support slowing of kidney function decline in patients with IgA nephropathy.

Fri Feb 13, 2026

$163.10 | +1.16%

Activity

ARWR: Strong Start for REDEMPLO Commercialization. By Business UpdateFirst Commercial Sales of REDEMPLO®Following its approval in November 2025 Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) recently announced encouraging news from the early commercial launch of REDEMPLO (plozasiran) as a treatment for adults suffering from familial chylomicronemia syndrome (FCS). Even with the Thanksgiving Christmas and New Years holidays the company reported that over 100 prescriptions for REDEMPLO have been rec

Wed Feb 11, 2026

$160.06 | +1.18%

Activity

Novartis: Value Price Growth Pipeline.

Thu Feb 5, 2026

$153.95 | +0.68%

Potential

Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead. Swiss pharmaceutical NVS) reported fourth-quarter 2025 results on Wednesday.The company'.s net sales 1% year over year to $13.34 billion missing Wall Street'.s . On a constant-currency (cc) basis sales were down 1%.Generic competition had a negative impact of 15 percentage points including a negative impact of 3 percentage points from revenue deduction adjustments in the United States mainly related to Entresto and Promact

Wed Feb 4, 2026

$152.91 | +2.04%

Potential

Novartis Beats on Q4 Earnings Entresto Generics Pressure Sales. NVS tops Q4 EPS estimates as margins expand but revenues miss the mark amid United States generics hitting Entresto and Promacta reshaping its growth mix.

Wed Feb 4, 2026

$152.91 | +2.04%

Earnings

Novartis reports mixed Q4 results. initiates FY26 soft outlook.

Wed Feb 4, 2026

$152.91 | +2.04%

Earnings

Discover NVS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of NVS. We're here to help you make informed investment decisions today.

FIND US ON

Receive our NVS Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NVS Stock trends

NVS Stock performance

NVS Stock analysis

NVS investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NVS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NVS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

NVS Stock Analysis & IQ Rating | Novartis AG

NVS Stock IQ

NVS Target Price

NVS Analysts Opinion

NVS Street Sentiment

NVS Risk Level

NVS Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our NVS Stock insights

Receive our NVS Daily Alerts

NVS Street Sentiment

NVS Risk Level

Key Price Levels

Latest Analyst Actions

Discover NVS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of NVS. We're here to help you make informed investment decisions today.

Receive our NVS Daily Alerts

NVS Alerts